DEA Extends Surveillance on Mail-Order Drug Deals
Published Date: 9/5/2025
Notice
Summary
The DEA is asking to keep collecting info about mail order drug sales without changing the current form. This affects businesses that sell drugs by mail and helps the government keep track of these transactions. No new costs or deadlines are coming, just a smooth extension to keep things running.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Mail‑Order Drug Sellers: Reporting Continues
If you run a business that sells drugs by mail, the DEA will keep collecting the same information using the existing Report of Mail Order Transactions form. This is an extension without change, so there are no new costs or new reporting deadlines — you must continue submitting the same reports to help the government track these transactions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in